Status:
COMPLETED
A Study of Medical Records From Children With Central Precocious Puberty (CPP) in China
Lead Sponsor:
Takeda
Conditions:
Central Precocious Puberty
Eligibility:
All Genders
Up to 18 years
Brief Summary
The main purpose is to describe how many children were treated during 24 months or less because of CPP and how treatment worked for them. There are no participants in this trial, the study only invol...
Detailed Description
This is an observational, non-interventional, retrospective study to evaluate the participants characteristics, current treatment patterns and resource usage in Chinese pediatric participants diagnose...
Eligibility Criteria
Inclusion
- • Participants diagnosed with CPP and treated with GnRHa from the centers participating in this study within the Chinese CPP Big Data Platform database since 2015 to 2024.
- CPP diagnosis is based on the clinical assessment and description by CPP specialized doctors.
Exclusion
- Not received GnRHa as the treatment for CPP.
- No available data for analysis.
Key Trial Info
Start Date :
December 13 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 27 2025
Estimated Enrollment :
1477 Patients enrolled
Trial Details
Trial ID
NCT05341128
Start Date
December 13 2023
End Date
August 27 2025
Last Update
September 2 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China, 530007
2
Hainan Women and Children's Medical Center
Haikou, Hainan, China, 570206
3
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, Hubei, China, 430030
4
Shandong Provincial Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, China, 250021